基于肠促胰素的治疗对糖尿病肾病的保护作用

Effects of incretin- based therapies on diabetic nephropathy

基于肠促胰素的治疗包括胰高血糖素样肽(GLP-1)受体激动剂和二肽基肽酶4(DPP-4)抑制剂,这类药物能够改善机体高血糖状态,保护β细胞功能,无体重增加,从而延缓糖尿病肾病病程的进展。此外,这类药物的胰腺外作用及GLP-1的依赖性和非依赖效应在糖尿病肾病中起着独特的作用,并引起广泛关注。本文综述了相关方面的前期临床和临床研究数据,提示这类药物对肾脏存在保护作用以及对血压及尿蛋白有改善作用,可能在糖尿病肾病中有着广泛的应用前景。

Incretin - based therapies in the treatment of patients with type 2 diabetes include Glucagon - like peptide - 1 （ GLP - 1 ） receptor agonists and dipeptidyl peptidase - 4 （ DPP - 4） inhibitors. This class of compounds can improve hyperglycemia,protect β -cell function without weight gain, which may partly prevent progression of diabetic nephropathy. Moreover,cumulative data suggest that incretin -based treatments interrupt the pathogenesis of diabetic nephropathy by their pleiotropic positive effects on kidney apart from decreasing glucose. This review focuses on these experimental and clinical studies to highlight the renoprotection effects of incretin - based therapies. Ongoing prospective studies are needed to clarify their possible role in the attenuation of diabetic nephropathy.